Diagnostics News and Research

RSS

Nuron Biotech licenses DNA amyloid beta 42 vaccine for AD

Nuron Biotech, Inc. today announced it has licensed from VITRUVIAN BioMedical, Inc. a gene-based (DNA) amyloid beta 42 (Aβ42) vaccine in preclinical development for Alzheimer's disease (AD).

9 Apr 2012

ISS recommends Illumina shareholders to vote against Roche's nominees

Roche released the following statement in response to a report issued by Institutional Shareholder Services recommending that shareholders of Illumina, Inc. vote against the election of Roche's independent director nominees to Illumina's Board of Directors.

From Illumina, Inc. 7 Apr 2012

Antibiotics may have absolutely no effect within a few decades

The increased resistance of bacteria to antibiotics is a global problem. Antibiotics are increasingly less effective. Microbiologist Dr. John Hays of Erasmus MC in Rotterdam is sounding the alarm: "The problem is so dire that within a few decades antibiotics will have absolutely no effect".

6 Apr 2012

Web-based worksite health promotion program minimizes absenteeism

Workers participating in a "comprehensive" workplace promotion program had a one-fifth reduction in absenteeism during the first year, reports a study in the April Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).

6 Apr 2012

Ameritox, Ridge Diagnostics partner to develop MDDScore test

Ridge Diagnostics, Inc., a neurodiagnostic company, announced today it has entered into an exclusive agreement with Ameritox, Ltd., a leader in medication monitoring, for the license rights to its proprietary developmental blood test MDDScore, a multiple biomarker analysis for Major Depressive Disorder (MDD) for primary care and pain physicians.

6 Apr 2012

New NewYork-Presbyterian autism center to open in early 2013

NewYork-Presbyterian Hospital, along with its affiliated medical schools Weill Cornell Medical College and Columbia University College of Physicians and Surgeons, today celebrated the start of construction on the new Center for Autism and the Developing Brain at the Hospital's Westchester campus in White Plains.

5 Apr 2012

Applied BioCode receives U.S. patent titled, ‘Light Transmitted Assay Beads’

Applied BioCode, Inc. today announced that the United States Patent and Trademark Office has issued US Patent #8,148,139 "Light Transmitted Assay Beads," describing the method of use and manufacturing of its Barcoded Magnetic Beads (BMB) products.

5 Apr 2012

Results from Abbott’s multiple interferon-free Phase 2 HCV studies to be presented at ILC 2012

Abbott will present clinical trial results from two different interferon-free, Phase 2 studies for the treatment of hepatitis C (HCV) at the International Liver Congress 2012 (ILC 2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain.

5 Apr 2012

CHD8, SNC2A and KATNAL2 gene mutations lead to ASDs

Mutations in three new genes have been linked to autism, according to new studies including one with investigators at Mount Sinai School of Medicine. All three studies include lead investigators of the Autism Sequencing Consortium.

5 Apr 2012

Navidea announces FDA extension of Lymphoseek PDUFA date by three months

Navidea Biopharmaceuticals, Inc. today announced that yesterday it received notification from the United States Food and Drug Administration (FDA) that the Prescription Drug User Fee Act (PDUFA) date for 99m-Tc-Tilmanocept, has been modified to September 10, 2012, a 90-day extension from the initial PDUFA date of June 10th.

4 Apr 2012

InstantLabs receives PTM certification for Salmonella Species Food Safety Kit

InstantLabs Medical Diagnostics Corporation, developer of the portable Hunter Accelerated Real-Time PCR system, today announced that its Salmonella Species Food Safety Kit has been certified as Performance-Tested Methods (PTM) No. 031202 by the AOAC Research Institute.

3 Apr 2012

Genomic fortune-telling fails to provide informative guidance to most people

With sharp declines in the cost of whole genome sequencing, the day of accurately deciphering disease risk based on an individual's genome may seem at hand. But a study involving data of thousands of identical twins by Johns Hopkins investigators finds that genomic fortune-telling fails to provide informative guidance to most people about their risk for most common diseases, and warns against complacency born of negative genome test results.

3 Apr 2012

NutraGene introduces first ever commercial type 2 diabetes genetic test

With the launch of the country's first ever commercial genetic test for type 2 diabetes, Indians will now have access to clinically relevant and cost effective genetic risk assessment services. NutraGene, a Delhi based genomics company that launched the tests believes that its type 2 diabetes genetic test will provide physicians an effective tool in assessing the risk of diabetes in the Indian population and will help in implementing personalized prevention and management strategies.

3 Apr 2012

MMRF announces unique oncology research partnership

The Multiple Myeloma Research Foundation (MMRF) today announced a unique oncology research partnership. This multi-year agreement involves several partners including the Translational Genomics Research Institute (TGen), Spectrum Health, and the Van Andel Research Institute.

3 Apr 2012

RainDance introduces new panel for cancer mutation screening

RainDance Technologies, Inc., the Digital Biology company, today announced the worldwide availability of its new panel for cancer mutation screening research using any next-generation sequencing (NGS) system.

2 Apr 2012

Life Technologies expands TaqMan Mutation Detection Assays

Life Technologies Corporation today announced the expansion to its TaqMan Mutation Detection Assays -- highly sensitive and novel molecular analysis research tools designed to detect an additional 241 of the most common mutations in 21 cancer genes.

2 Apr 2012

Ingenuity iReport for Real-Time PCR optimized for TaqMan Gene Expression Assays

Ingenuity Systems, a leading provider of information and analysis solutions for life science researchers, and Life Technologies Corporation today announced Ingenuity iReport for Real-Time PCR optimized for TaqMan Gene Expression Assays.

2 Apr 2012

TGen to present TNBC study at AACR 2012 annual meeting

Because cases of Triple-Negative Breast Cancer (TNBC) are so genetically different, whole-genome sequencing is needed to detect the subtle molecular differences that might point to specific treatments for individual patients.

2 Apr 2012

Dyax, GE Healthcare partner to develop and commercialize c-Met imaging peptides

GE Healthcare, a unit of GE, and Dyax Corp. today announced a licensing agreement for the development and commercialization of peptides binding to c-Met, which provides upfront, milestone, and royalty payments to Dyax.

2 Apr 2012

New breast cancer gene mutation discovered

A large international study led by University of Melbourne researchers has identified a mutation linked to breast cancer attached to the newly identified gene, called XRCC2. Lead researcher Melissa Southey said the discovery, using high-speed technology, would hopefully mean that more gene mutations responsible for causing breast cancer could be rapidly identified in the next few years.

1 Apr 2012